Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
Drugs by status
Phase 4 trials (5)
Phase 3 trials (4)
Phase 2 trials (45)
- gallium-68-dotatate
- abemaciclib
- anti-ny eso-1 mtcr pbl
- antineoplaston AS2-1
- atengenal
- autologous tumor infiltrating lymphocytes
- olaparib
- brigatinib
- irinotecan
- vismodegib
- imatinib
- gsk2256098
- aldesleukin
- hydroxyurea
- nivolumab
- pembrolizumab
- regorafenib
- octreotide
- pasireotide
- perillyl alcohol
- ifosfamide
- ipilimumab
- sunitinib
- cyclophosphamide
- bevacizumab
- everolimus
- trabectedin
- verapamil
- vistusertib
- cabozantinib
- +15 more
Phase 1 trials (37)
- 177lu-dota-jr11
- avelumab
- urea
- lenalidomide
- cilengitide
- ef5
- gemcitabine
- trametinib
- ar-42
- 13c-pyruvate
- Filgrastim
- ispinesib
- ribociclib
- o6-benzylguanine
- dordaviprone
- palbociclib
- panobinostat
- alpelisib
- ro4929097
- sonidegib
- temozolomide
- allogeneic lymphocytes
- bortezomib
- veliparib
- vorinostat
- alloreactive ctl
- cediranib
- romidepsin
- pioglitazone
- oxygen
- +7 more
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (43)
- Takeda
- AstraZeneca
- Merck
- Genentech
- Pfizer
- Novartis
- GlaxoSmithKline
- NovoCure Ltd.
- National Institutes of Health (NIH)
- University of Pittsburgh
- Burzynski Research Institute
- Cedars-Sinai Medical Center
- Centre Leon Berard
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Duke University
- Johns Hopkins University
- New York University
- Northwestern University
- University of Iowa
- UNICANCER
- University of Miami
- University of Sydney
- University of Bologna
- Wake Forest University
- Wayne State University
- University of Virginia
- Mayo Clinic
- Tel Aviv University
- +13 more
Organization Involved with Phase 1 Indications (14)
- Oncoceutics, Inc.
- University of Pennsylvania
- University of Arizona
- Barrow Neurological Institute
- Ohio State University
- Pediatric Brain Tumor Consortium
- Stanford University
- Thomas Jefferson University
- University of California, Los Angeles
- City of Hope National Medical Center
- Washington University in St. Louis
- Developmental Therapeutics Consortium
- Actuate Therapeutics Inc.
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (3)